Q-omics provides the consensus-scored TMEM19 profile across patient tissues and cancer cell-line models. TMEM19 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM19 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TMEM19 protein abundance shows 23,773 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, THCA, and LUAD as cancer lineages where TMEM19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM19 survival associations across molecular data types. TMEM19 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM19 RNA expression–survival associations across cancer types. High TMEM19 expression shows unfavorable associations in UVM, MESO, LGG and ACC, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM19 RNA expression.
This table summarizes TMEM19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM19 shows lower tumor expression in THCA, COAD, KICH and LUAD and higher tumor expression in LIHC and BRCA. The THCA box plot shows higher TMEM19 RNA expression in normal versus tumor tissue (log2 FC = −1.224, t-test p < 0.001).
This table shows molecular features associated with TMEM19 in patient tissues and cancer cell lines. In patient samples, TMEM19 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
